OncoMatch/Clinical Trials/NCT06730256
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Is NCT06730256 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CAR-T cells Infusion chimeric antigen receptor T cells for relapsed/refractory plasma cell leukemia.
Treatment: CAR-T cells Infusion chimeric antigen receptor T cells — A Clinical Study to Explore the Safety, Efficacy, and Cellular Metabolic Dynamics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Patients with R/RMM who have received at least 3 prior lines of therapy, including at least 1 proteasome inhibitor and at least 1 immunomodulator (IMiD)
Must have received: immunomodulator
Patients with R/RMM who have received at least 3 prior lines of therapy, including at least 1 proteasome inhibitor and at least 1 immunomodulator (IMiD)
Must have received:
Patients with RRpPCL had received at least 1 prior line of therapy
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks prior to signing informed consent
autologous stem cell transplantation within 12 weeks prior to signing informed consent
Cannot have received:
Exception: treatment for the disease within 14 days before informed consent
Have received treatment for the disease within 14 days before informed consent
Cannot have received: cell therapy
Exception: within 28 days before informed consent
Have received cell therapy within 28 days before informed consent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify